In a randomized pilot trial of 62 type 2 diabetes patients, the minor cannabinoid THCV significantly lowered fasting blood sugar and improved pancreatic beta-cell function, while CBD had more modest effects.
Read this if you have type 2 diabetes and are interested in how cannabinoids might affect blood sugar control.
THCV lowered fasting blood sugar by 1.2 mmol/L and improved beta-cell function
What the researchers found
This was the first randomized controlled trial testing cannabinoids specifically for glycemic control in type 2 diabetes. Sixty-two patients with non-insulin-treated diabetes were randomized to five groups: CBD alone, THCV alone, low-ratio CBD:THCV, high-ratio CBD:THCV, or placebo for 13 weeks.
THCV was the clear standout. Compared to placebo, it significantly decreased fasting blood sugar, improved pancreatic beta-cell function, increased the beneficial hormone adiponectin, and improved apolipoprotein A levels. However, it did not affect HDL cholesterol (the primary endpoint).
CBD showed more modest effects, decreasing the inflammatory marker resistin and increasing the gut hormone GIP compared to baseline, but these changes were not significant compared to placebo.
Surprisingly, the combination treatments (CBD plus THCV) had no significant impact on any endpoint, suggesting the compounds may interfere with each other.
Why it matters
THCV is a minor cannabinoid found in small amounts in some cannabis varieties. This trial provides the first human evidence that it has genuine metabolic effects in diabetes patients. If confirmed in larger trials, THCV could represent an entirely new class of diabetes medication derived from cannabis.
The numbers in context
THCV decreased fasting glucose by 1.2 mmol/L vs. placebo (p<0.05). Beta-cell function improved by 44.51 points (p<0.01). Adiponectin increased (p<0.01). CBD decreased resistin by 898 pg/ml (p<0.05 vs. baseline). 62 patients, 13-week treatment. Both compounds were well-tolerated.
How the study worked
Randomized, double-blind, placebo-controlled, parallel-group pilot study. Sixty-two subjects with non-insulin-treated type 2 diabetes across five treatment arms for 13 weeks. CBD was dosed at 100 mg twice daily and THCV at 5 mg twice daily. Primary endpoint: HDL cholesterol change. Extensive secondary and tertiary metabolic endpoints.
What this study cannot tell us
Small pilot study (62 patients across 5 arms means very small per-group sizes). The primary endpoint (HDL) was not met. Thirteen weeks may be too short to see full metabolic effects. THCV is available in very limited quantities, which would constrain clinical development.
How to read the evidence
Randomized double-blind placebo-controlled trial, but small pilot study with multiple arms resulting in very small group sizes.
When this study was published
Published in 2016. THCV research for metabolic conditions remains in early stages due to limited compound availability.
The bigger picture
Type 2 diabetes affects hundreds of millions of people globally. The discovery that a cannabis-derived compound can improve blood sugar control and beta-cell function in humans is significant, especially because THCV is non-psychoactive. The failure of the combinations is also important, as it suggests that more is not always better with cannabinoid therapeutics.
Questions still open
- Would larger, longer THCV trials confirm these findings? Why did the CBD-THCV combinations fail to show effects? Could THCV be developed as a diabetes medication if supply challenges are overcome?
Common questions
Can cannabis lower blood sugar?
Does CBD help with diabetes?
Read the original research
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.
Diabetes care, 39(10), 1777-86
Citation
Jadoon, Khalid A; Ratcliffe, Stuart H; Barrett, David A; Thomas, E Louise; Stott, Colin; Bell, Jimmy D; O'Sullivan, Saoirse E; Tan, Garry D. (2016). Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.. Diabetes care, 39(10), 1777-86. https://doi.org/10.2337/dc16-0650
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk